Gain Therapeutics (GANX) Net Cash Flow (2020 - 2026)

Gain Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$3.3 million in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 25.9% year-over-year to -$3.3 million in Q2 2026; TTM through Jun 2026 was $6.4 million, a 160.92% increase from a year earlier, with the FY2025 full-year figure at $10.0 million, up 1228.91% from the prior year.
• Net Cash Flow was -$3.3 million for Q2 2026 at Gain Therapeutics, up from -$4.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $11.9 million in Q4 2025, with the low at -$19.9 million in Q2 2022.
• Average Net Cash Flow over 5 years is -$1.3 million, with a median of -$1.7 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow tumbled 477.38% in 2022, then jumped 2741.25% in 2024.
• Over 5 years, Net Cash Flow stood at -$3.8 million in 2022, then soared by 285.69% to $7.0 million in 2023, then slumped by 116.83% to -$1.2 million in 2024, then jumped by 1106.77% to $11.9 million in 2025, then slumped by 127.77% to -$3.3 million in 2026.
• The last three Net Cash Flow figures came in at -$3.3 million (Q2 2026), -$4.3 million (Q1 2026), and $11.9 million (Q4 2025), per Business Quant data.